Collegium Pharmaceutical, Inc. COLL Net accretion for deferred royalty obligation

Other financials

Revenue$193.5M+8.9%

Gross profit$117.2M+20.5%

Operating income$30.9M+42.5%

Net income$14.5M+500%

EPS (diluted)$0.40+471%

Cash & equivalents$289.6M+147%

Total debt$5.2M-19.5%

Total equity$312.4M+33.3%

Total assets$1.7B+1.3%

Operating cash flow$57.1M+3.1%

CapEx$270.0K-66.2%

Free cash flow$56.8M+4.1%

Market cap$1.15B+17.9%

Enterprise value$869.67M-0.3%

P/E15.4×-6.9×

P/S1.5×0.0×

Gross margin60.7%+3.0pp

Operating margin23.7%+2.3pp

Net margin9.4%+2.8pp

FCF margin41.4%+10.4pp

Return on equity27.4%+8.2pp

Debt / equity0×0.0×

Current ratio1.7×+0.6×

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept coll:NetAccretionForDeferredRoyaltyObligation.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Collegium Pharmaceutical, Inc.'s net accretion for deferred royalty obligation?: Collegium Pharmaceutical, Inc. (COLL) reported net accretion for deferred royalty obligation of $71K in Q1 2026.